Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

NCT03308201 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Hemay022+exemestane
DRUG: Hemay022+letrozole
DRUG: Hemay022+ fulvestrant

Sponsor

Tianjin Hemay Pharmaceutical Co., Ltd